ESTRO 35 2016 _____________________________________________________________________________________________________ setting remains still controversial, despite the large consensus as a promising candidate to become a biomarker that could further improve application and efficacy of radiation therapy (RT) in head and neck squamous cell carcinoma (HNSCC). Moreover, most of the studies refer to series of patients who underwent RT alone or in combination with Cetuximab. We performed a retrospective analysis on the prognostic value of EGFR expression in HNSCC treated with surgery and postoperative RT.
setting remains still controversial, despite the large consensus as a promising candidate to become a biomarker that could further improve application and efficacy of radiation therapy (RT) in head and neck squamous cell carcinoma (HNSCC) . Moreover, most of the studies refer to series of patients who underwent RT alone or in combination with Cetuximab. We performed a retrospective analysis on the prognostic value of EGFR expression in HNSCC treated with surgery and postoperative RT.
Material and Methods:
We analyzed 69 patients with an histological diagnosis of HNSCC who underwent adjuvant RT after surgery in our Institute from 1997 to 2003. A 3D conformal RT was delivered with a 6MV accelerator using a conventional fractionation (median 60 Gy, range 34.2-70 Gy) Median follow-up was 3.73 years (range 0.17-12.25 ys). None of these patients were treated with postoperative concomitant chemotherapy. Tumor samples used for the determination of EGFR were obtained from surgical specimens. Membrane features (intensity, extension, distribution) and percentage of EGFR expression were evaluated and a statistical analysis (univariate) was conducted to correlate these parameters with Overall Survival (OS) and Disease Free survival (DFS).
Results: EGFR was overexpressed in 45,5% of our patients (median value used as threshold). No significant correlation (p value= 0.90) has been found between patients with an overexpression of EGFR and OS or DFS. Among patients with laryngeal carcinoma, those with overexpressed EGFR have showed a lower OS (not statistically significant) and DFS (p=0.05). Considering separately the membrane features, the intensity of the EGFR staining has been found statistically correlated with both OS (p= 0.03) and DSF (p= 0.001). Moreover, a stratification of patients was performed combining extension and intensity of EGFR immunolabelling in tumour cell membranes, and their distribution following a three-point score: patients with 3+ score (intense and complete labelling and patchy distribution) presented the lowest OS and DFS and the difference was highly significant for both OS and DFS (p= < 0.0001). The same result was observed in the subgroup of patients with a diagnosis of larynx carcinoma.
Conclusion:
Based on our results it is still reasonable that the analysis of EGFR expression, especially referring to membrane features, might be a prognostic value for OS and DFS in locally advanced HNSCC treated with adjuvant RT. A clinical validation in prospective trials of the suggested three-point score system could be useful to select patients with worse prognosis that might benefit from more aggressive treatments. Purpose or Objective: Tumor hypoxia is a common feature of locally advanced head and neck cancer (HNSCC) that is associated with higher malignancy and increased radioresistance. Tumor-to-blood ratios ≥1.2 are generally thought to indicate hypoxia. Nevertheless, previous studies use various thresholds to define tumor hypoxia. The following analysis tries to elucidate which threshold may be the most appropriate to determine hypoxic volume in respect to treatment success.
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Material and Methods:
A prospective study was performed to determine changes in tumor hypoxia during primary chemoradiation (pRCTx) of HNSCC at our institution. Tumor hypoxia was non-invasively assessed by [18F]-Fluoro-Misonidazole (F-MISO) PET/CT 2.5 h p.i. at baseline (week 0) and in week 2 and 5 of treatment, respectively. Hypoxic volumes (HV) were generated using thresholding at different levels of 1.2, 1.3, 1.4, 1.5 multiplied with the backgrounduptake, which was defined as SUVmean within the ipsilateral trapezium muscle, as advised by a nuclear-medicine specialist. ∆-values of decrease of HV (∆HV) during treatment were obtained in weeks 0, 2 and 5 and correlated with local failure. As four patients showed local failure (LF), two groups of four patients each were made: four showing LF, four patients showing complete remission (CR). Before t-test analysis normal sample distribution was confirmes with Shapiro-Wilk test. Significance-level was defined as p<0.005.
Results:
We analysed 4 patients without local failure in comparison to 4 patients with LF to show differences of ∆values in weeks 0 to 2, 2 to 5 and 0 to 5 of the HV. All patients primarily treated for HNSCC with dRCTx were included. Each patient received a total dose of 70Gy in 35 fractions. Concomitant cisplatin chemotherapy was administered in weeks 1, 4 and 7. The mean follow-up time was 16.9 months (range: 10-22 months). Mean time to LF was 9.5 months (range: 6-15 months). For patients in CR all ∆ -HV (mean) show proportional decrease in weeks 0 to 5. This is true for every threshold factor from 1.2 to 1.5. In those patients showing LF, ∆ -HV (mean) demonstrates not only a decrease in HV but also some increase at each of the time increments. There is a general decrease (p=0.0073) between week 0 and 5, while between week 0 and 2 and 2 and 5, a rise in ∆ -HV(mean) can be shown (p=0.2339, p=0.0649, respectively).
Conclusion:
A decrease in ∆ -HV (mean) was shown at any time point, for any factor the tumor-to-background-ratio was multiplied with, in patients with CR. In patients with LF, the hypoxic volume showed inconsistence over time, at least at one time of measurement there was an increase in hypoxic volume. The choice of the threshold for determination of hypoxic volume in FMISO-PET/CT remains a crucial question that could not be answered at this point. To elucidate this larger patient numbers are needed. 
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